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Abstract
Background: The Global Vaccine Action Plan will require, inter alia, the mobilization of financial resources from donors and
national governments – both rich and poor. Vaccine Procurement Assistance (VPA) and Vaccine Procurement Baseline (VPB)
are two metrics that could measure government performance and track resources in this arena. VPA is proposed as a new
subcategory of Official Development Assistance (ODA) given for the procurement of vaccines and VPB is a previously
suggested measure of the share of Gross Domestic Product (GDP) that governments spend on their own vaccine
procurement.
Objective: To determine realistic targets for VPA and VPB.
Methods: Organization for Economic Co-Operation and Development (OECD) and World Bank data for 2009 were analyzed
to determine the proportions of bilateral ODA from the 23 Development Assistance Committee (DAC) countries disbursed
(as % of GDP in current US$) for infectious disease control. DAC country contributions to the GAVI Alliance for 2009 were
assessed as a measure of multilateral donor support for vaccines and immunization programs.
Findings: In 2009, total DAC bilateral ODA was 0.16% of global GDP and 0.25% of DAC GDP. As a percentage of GDP,
Norway (0.013%) and United Kingdom (0.0085%) disbursed the greatest proportion of bilateral ODA for infectious disease
control, and Norway (0.024%) and Canada (0.008%) made the greatest contributions to the GAVI Alliance. In 2009 0.02% of
DAC GDP was US$7.61 billion and 0.02% of the GDP of the poorest 117 countries was US$2.88 billion.
Conclusions: Adopting 0.02% GDP as minimum targets for both VPA and VPB is based on realistic estimates of what both
developed and developing countries should spend, and can afford to spend, to jointly ensure procurement of vaccines
recommended by national and global bodies. New OECD purpose codes are needed to specifically track ODA disbursed for
a) vaccine procurement; and b) immunization programs.
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Introduction
In December 2010, global health leaders committed to making
the next 10 years the Decade of Vaccines – to ensure discovery,
development, and delivery of lifesaving vaccines globally, espe-
cially for the benefit of the poorest countries [1]. To meet the goals
of the Decade of Vaccines (2011–2020), Ministers of Health from
194 countries endorsed a Global Vaccine Action Plan in May
2012 [2]. This plan calls for increased funding for immunization,
including commitments by governments to invest in immunization
commensurate with their ability to pay. It also calls for efforts to
seek funds from new domestic sources as well as from international
donors.
The Vaccine Procurement Baseline (VPB) has been previously
suggested as a strategy to enhance transparency, equity, and
sustainability in funding vaccine procurement for immunization
programs [3]. Based on an analysis of Gross Domestic Product
(GDP), population, and crude birth rate in countries with
approximately $500 GDP per capita, it was shown that about
0.01% of GDP would be required to purchase all Expanded
Program on Immunization vaccines in 1998. During the same
period, developed countries allocated in excess of 0.01% of GDP
(US, 0.035%; UK 0.0163%; Canada 0.0175%) to provide the
traditional Expanded Program on Immunization vaccines plus a
number of new vaccines. The original VPB proposal required that
all countries spend a minimum of 0.01% of GDP on vaccine
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procurement, and that if recommended vaccines could not be
obtained with those funds, the balance would be paid by external
sources [3].
Official Development Assistance (ODA) is described as ‘‘[f]lows
of official financing administered with the promotion of the economic
development and welfare of developing countries as the main objective, and
which are concessional in character with a grant element of at least 25 percent
(using a fixed 10 percent rate of discount). By convention, ODA flows comprise
contributions of donor government agencies, at all levels, to developing countries
(‘‘bilateral ODA’’) and to multilateral institutions. ODA receipts comprise
disbursements by bilateral donors and multilateral institutions. Lending by
export credit agencies – with the pure purpose of export promotion – is
excluded’’ [4]. In October 1970 the United Nations General
Assembly passed resolution 2626, which included the goal that
‘‘each economically-advanced country will progressively increase its official
development assistance to the developing countries and will exert its best efforts
to reach a minimum net amount of 0.7% of its gross national product at
market prices by the middle of the Decade’’ [5]. Sweden and the
Netherlands were first to achieve this target in 1975, followed by
Norway (1976) and Denmark (1978) [5].
Immunization is well accepted as one of the most cost-effective
of all health interventions [2,6]. However, it is likely that the
economic benefits of investing in vaccination programs have been
underestimated since traditional economic and disease reduction
evaluations do not consider the following: healthy children
perform better at school; healthy adults are more productive and
better able to care for their children’s health and education;
healthier families are more likely to save for the future and to have
fewer children; and healthier societies are more likely to attract
more foreign direct investment including tourism [7,8]. Failure to
consider these broader benefits of vaccination could prevent the
benefits of immunization being fully realized [9]. Recent estimates
suggest that over the decade to 2020, immunization will save more
than US$ 2.6 billion in averted treatment costs, lost caretaker
wages and lost productivity in the world’s poorest countries [6].
Monitoring costs to fully vaccinate a child requires monitoring
the costs of both vaccine procurement and the costs of providing
immunization programs (Figure 1). This study focuses on the cost
of vaccine procurement for routine immunization only. Delivery
costs and costs (vaccine and delivery) for catch-up immunization,
when necessary, are important, but policy makers are often first
concerned with the per dose cost of a vaccine for routine
immunization. This is because, for new vaccines, the per dose costs
are often an order of magnitude greater than the estimated
delivery costs and the routine immunization vaccine costs will
most often extend indefinitely while catch-up can be completed in
a few years. Also it is likely that monitoring expenditures for
immunization programs will be significantly more challenging
than monitoring expenditures on vaccine procurement, since
immunization programs overlap with other maternal, newborn,
and child health (MNCH) services (Figure 1).
We herein analyze data from the Organization for Economic
Co-Operation and Development (OECD) and the World Bank to
determine the total proportion of bilateral ODA disbursed in 2009
as % of 2009 GDP in current US$, the proportion allocated for
social programs in the least developed countries (LDC), and the
proportion of bilateral ODA allocated to infectious disease control
(as an approximate estimate of bilateral ODA currently allocated
for immunizations). Data from the GAVI Alliance (GAVI) are
assessed to obtain a lower-bound estimate of current multilateral
contributions made by donor countries for vaccines procurement
and strengthening immunization programs. We propose to
combine the previous concept of VPB (share of GDP allocated
by national governments for vaccine procurement) with a new
concept of Vaccine Procurement Assistance (VPA), where VPA
would be defined as official financing, via grants, for vaccine
procurement.
Figure 1. Monitoring costs to fully vaccinate a child requires monitoring the costs of both vaccine procurement and the costs of
providing immunization programs.
doi:10.1371/journal.pone.0089593.g001
VPA and VPB
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Figure 2. Richest 40 countries in 2009 based on gross domestic product (GDP) per capita measured in current US$.
doi:10.1371/journal.pone.0089593.g002
Figure 3. Sub-categories of bilateral official development assistance in 2009 for the 23 Development Assistance Committee (DAC)
countries as a share of their gross domestic product (GDP) in current 2009 US$.
doi:10.1371/journal.pone.0089593.g003
VPA and VPB
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Methods
OECD data
The OECD website provides a detailed database of disburse-
ments made by the 23 Development Assistance Committee (DAC)
countries that report to the Creditor Reporting System [10]. Gross
disbursements (in constant 2009 US$) for bilateral ODA were
downloaded on 20 December 2011. The Creditor Reporting
System database has selectable filters on the website that allowed
the following donor country comparisons to be made:
Figure 4. Bilateral official development assistance (ODA) allocated for infectious disease control and contributions to the GAVI
Alliance (GAVI) in 2009 for the 23 Development Assistance Committee (DAC) countries as a share of their gross domestic product
(GDP) in current 2009 US$. Countries ranked according to total bilateral ODA as a proportion of GDP disbursed in 2009.
doi:10.1371/journal.pone.0089593.g004
Table 1. Estimated costs of achieving WHO-UNICEF Global Immunization Vision and Strategy by scaling up use of traditional,
underused and new vaccines in GAVI-eligible and low- and lower-middle income countries [14] and extrapolated costs for upper-
middle-income and Development Assistance Committee (DAC) countries as percentage of 2009 gross domestic product (GDP)
measured in current US$.
Total cost of vaccines
and immunization
per year US$ billion
Cost of vaccines and
immunization as
% 2009 GDP
Cost to fully
vaccinate
a child US$
Cost to fully vaccinate a
child as proportion of
2009 GDP per capita
Poorest 117 countries [14] 7.6 (2.3–11) 0.053% a 56 2.11% a
72 GAVI-eligible
countries [14]
3.5 (1.3–4) 0.107% a 39 3.56% a
45 low- and lower-middle-
income countries [14]
4.2 (1.1–7) 0.038% a 92 2.02% a
Upper-middle-
income countries
2.15 b 0.045% b 255 b 2.11% b
DAC countries 11.5 b 0.03% b 843 b 2.11% b
Total 21.4 a,b 0.037% a,b
Footnotes:
aBirth data missing for Dominica, Kiribati, Palau, Marshall Islands, Seychelles, St. Kitts and Nevis, and Tuvalu and GDP data missing for Cuba, Democratic People’s
Republic of Korea, Marshall Islands, Myanmar, Somalia and Tuvalu.
bAssumes that with tiered pricing the cost to vaccinate a child in upper-middle-income and DAC countries would also be 2.11% of GDP per capita.
doi:10.1371/journal.pone.0089593.t001
VPA and VPB
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1. Total bilateral ODA versus bilateral ODA grants (using filter
‘‘flow’’);
2. Total bilateral ODA to all 172 pre-selected recipient countries
versus bilateral ODA only to the LDCs (using filter ‘‘income
group’’);
3. Total bilateral ODA versus bilateral ODA for social infra-
structure and services (using filter ‘‘sector’’);
4. Total bilateral ODA versus bilateral ODA only to public sector
(using filter ‘‘channel’’);
5. Total bilateral ODA versus bilateral ODA only for infectious
disease control (using filter ‘‘purpose code’’ = 12250).
Infectious disease control includes ODA disbursed for (a)
immunization; and (b) prevention and control of infectious and
parasitic diseases, but excludes ODA for malaria control,
tuberculosis control, and control of HIV/AIDS and other sexually
transmitted diseases). Purpose code 12220 for basic health care
includes ODA for: basic and primary health care programs;
paramedical and nursing care programs; supply of drugs,
medicines and vaccines related to basic health care. However
only the infectious disease control filter was used to provide an
approximate estimate of bilateral ODA that a country might have
allocated for immunization programs, since the basic health care
filter was considered too broad.
GAVI data
Since 2000, GAVI has been the main multilateral agency that
provides funding for vaccine procurement for the LDCs. DAC
country contributions to GAVI for 2009 [11], thus serve as an
approximate lower estimate of multilateral ODA allocated for
vaccine procurement. These GAVI contributions included direct
contributions, contributions to the International Finance Facility
for Immunization, contributions to the Advance Market Com-
mitment program, and contributions to GAVI’s Matching Fund.
Thus, although bilateral ODA for infectious disease control and
GAVI contributions do not provide the full picture of donor
country support for vaccine procurement, these data provide some
perspective of what could be realistic contributions that countries
could make as a proportion of their GDP.
World Bank data
World Bank data allow access to a number of different
databases searchable according to various criteria [12]. Using
the World Development Indicators and Global Development
Finance database, the following country-level data for 2009 were
downloaded for countries: total population; GDP (current US$);
GDP, purchasing power parity (current international $). The
richest 40 territories or countries were ranked according to their
GDP per capita (current US$) (Figure 2). Affluent non-DAC
countries were excluded from further analysis as ODA data on
these countries are not included in the OECD Creditor Reporting
System database. ODA and the various sub-categories of ODA
were calculated for each country as % of GDP (current US$).
Results
In 2009 only two countries (Norway and Sweden) disbursed
more than 0.7% of their GDP as bilateral ODA (Figure 3) [5], and
only three countries (Luxembourg, Norway and Ireland) gave
more than 0.1% of their GDP for social programs in the LDCs as
part of their bilateral ODA programs (Figure 3) [13]. However, if
only the grant aid disbursed for social programs in the LDCs is
considered, then no country achieved a level of even half of 0.1%
of GDP for this form of ODA (Figure 3).
In 2009 global GDP was US$ 57.9 trillion [12], and DAC GDP
was US$ 38.1 trillion [10]. In the same year, total DAC bilateral
and multilateral ODA was US$ 134 billion (0.23% of global GDP
and 0.35% of DAC GDP) and DAC bilateral ODA was US$
94.7 billion (0.16% of global GDP and 0.25% of DAC GDP).
DAC bilateral ODA was 70.7% of total DAC ODA for 2009.
Figure 5. Example of a score card to show how Norway is performing relative to other countries for its Vaccine Procurement
Assistance, defined as ‘‘grant aid provided by national donor governments to procure vaccines as a share of gross domestic product (GDP)’’.
doi:10.1371/journal.pone.0089593.g005
VPA and VPB
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The greatest proportion of their GDP for infectious disease
control (OECD purpose code 12250) was given by Norway
(0.013%), followed by the United Kingdom (0.0085%) (Figure 4).
Although government (public sector) ownership of national
immunization programs might be anticipated to provide the most
equitable and comprehensive provision of services, less than half of
the bilateral ODA disbursed for infectious disease control was
allocated to the public sector (Figure 4). In 2009 GAVI received
US$ 676.1 million in contributions; 82% of this came from 14
DAC countries, with the majority coming from seven: Canada
(19.0%), Norway (15.9%), Italy (15.8%), United States of America
(13.5%), France (10.1%), the Netherlands (8.2%), and United
Kingdom (8.1%) [11]. As a proportion of their GDPs, Norway
(0.024%), Canada (0.008%) and the Netherlands (0.006%) gave
the greatest contributions to GAVI in 2009 (Figure 4). We
combined contributions to GAVI and bilateral ODA for infectious
disease control for 2009 to explore what could be a realistic target
for VPA. The greatest proportion of their GDP for these
combined contributions was given by Norway (0.036%), Canada
(0.014%) and the United Kingdom (0.011%).
The WHO-UNICEF Global Immunization Vision and Strategy
has a goal of reducing mortality due to vaccine-preventable
diseases by two-thirds by 2015 [14]. This will require scaling up
use of traditional and underused vaccines, as well as the
introduction of new vaccines. The estimated cost of doing this
for the 10-year period 2006 to 2015 was US$ 76 billion for 72
GAVI-eligible (for 2005–2010 included countries with 2003 gross
national income per capita , US$ 1000) and 45 low- and lower-
middle income countries, i.e., US$ 7.6 billion/year. Costs
included in this study were baseline costs, vaccine costs, systems
costs and campaign costs. If only current routine immunization is
maintained then 25% of the costs were for vaccines, but with
scaling up, 60% of the costs were for vaccines. On an annual basis
for 2009 this US$ 7.6 billion/year equated to 0.107% of GDP for
the 72 GAVI-eligible countries and 0.038% of GDP for the 45
low- and lower-middle-income countries (Table 1). To make an
approximate estimate of the VPB costs for the upper-middle-
income and DAC countries, we assumed that with tiered pricing
the costs would be a similar proportion of GDP/capita (2.11%)
and respectively equate to US$255 and US$843 per child, 0.045%
and 0.03% as % of GDP, and 2.15 billion and 11.5 billion in total
costs (Table 1). Although very approximate, these estimates are
within previous ranges [3].
Discussion
We propose that VPA be a clearly defined and specific
subcategory of ODA and that all donor governments commit to
allocating more than 0.02% of GDP for vaccine procurement for
recipient countries. A target of 0.02% is also proposed for VPB,
i.e. the share of GDP spent on vaccine procurement by all national
governments. Monitoring VPA and VPB, and reporting which
rich countries give less than 0.02% of their GDP for vaccine
procurement in poorer countries and which national governments
spend less than 0.02% of GDP on their own vaccine procurement,
could be a powerful advocacy tool to encourage greater giving and
greater spending. Conceptually, the benchmark of 0.02% of GDP
for both VPA and VPB provides a starting point for realistic
funding targets. However with potential changes in the near
future, such as improved documentation of expenditures for
vaccine procurement and immunization programs, with the
development of new vaccine technologies and delivery systems,
and with increased experience with a variety of funding
mechanisms, it is likely that the 0.02% targets for VPA and
VPB will need to be adjusted upwards or downwards in the future.
We used cost estimates for 2006 to 2015 for the 117 poorest
countries [14], but more recent estimates for 2011 to 2020 for 94
low- and lower middle-income countries suggest that costs could
be only US$ 5.75 billion per year during the Decade of Vaccines
Figure 6. Example of a score card to show how a country of any income status is ‘‘under-performing’’ relative to others for the
metric Vaccine Procurement Baseline, defined as ‘‘share of gross domestic product spent on vaccine procurement’’.
doi:10.1371/journal.pone.0089593.g006
VPA and VPB
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[15]. Bill Gates has suggested that ‘‘Setting clear goals and finding
measures to mark progress, together with raising the funds for
health and development projects will be necessary to sustain the
momentum of the past 15 years in improving lives of the poorest’’
[16]. We believe that presenting costs of vaccine procurement and
immunization programs in terms of a percentage of GDP provides
simple and transparent measures to mark progress, as well as
providing a tool to advocate for more funds.
Recent analyses have assessed ODA spending in relation to
MNCH [17–20]. Although there have been increases to total
worldwide ODA, including that allocated to MNCH, these
absolute increases were not linked to increases in donor GDP
[20]. In 2009 total bilateral and multilateral ODA in US$,
excluding debt forgiveness, was US$ 132.36 billion (12.5% for
health; 4.9% for MNCH; 3.7% for MNCH in the 74 priority
countries with high child mortality as tracked by the ‘‘Countdown
to 2015 Initiative’’; and 0.48% (0.6382 billion) for immunization
in these 74 countries) [20]. With DAC total ODA representing
0.35% of DAC GDP in 2009, we can estimate that in 2009 VPA
for the 74 priority countries could have been no more than
0.0017% of DAC GDP (0.6382/[132.36/0.0035]). However, in
2009 Norway gave 0.024% of its GDP directly to GAVI, showing
that a 0.02% VPA target is achievable for countries that are
committed to it (Figure 4). This contribution was also possible at
the height of the Global Financial Crisis when it is likely that some
countries were reducing their ODA. For this reason it is also
possible that the 2009 figures used in our analysis may illustrate an
under-, rather than overestimate of typical annual ODA.
Donor funds for procurement of children’s vaccines are needed
for three reasons. First, they address the shared global responsi-
bility for achieving equity between developed and developing
countries. Children in industrialized countries receive new
vaccines as soon as they become available, whereas this is not
the case in many developing countries. A system-wide change is
required to achieve equity. Second, vaccines are an international
public commodity (a public good). Responsibility for health may
lie at the national government level but the determinants of health
and the means for governments to fulfill that responsibility are
increasingly global. The third reason has to do with the economics
of the vaccine industry. For vaccines, the greater the volume or
number of manufacturers, the lower will be the price. Industry
cites the high cost of product development and capital investment
for production facilities as rationales for high vaccine prices, but
extremely high profit margins in the pharmaceutical industry and
high expenses on product promotion raise questions about these
rationales.
A 2001 survey reported that 70% to 90% of the public from 13
DAC countries supported the principle of providing ODA to
developing countries [21]. Yet there appear to be major
misconceptions about the amount of ODA allocated, with a
recent US survey showing that the American public vastly
overestimated the amount of US foreign aid – believing it in the
region of 25% of the federal budget when in fact it was only 1%
[22]. The respondents considered that about 10% of the federal
budget would be a reasonable allocation for aid. We can speculate
how the public would react to these questions if they realized that
most ODA is not allocated for poverty alleviation, with only a
relatively small fraction of ODA going to social programs in the
poorest countries (Figure 3). Although most donors in 2009 gave
all or the majority of the ODA as grant aid (data not shown), there
were still some countries giving some ODA as repayable loans.
One might anticipate that there could be strong public support for
donor governments to disburse 0.1% of GDP for genuine poverty
alleviation programs [13], and many people, if genuinely
informed, might wish to see the full amount of recommended
ODA (0.7% of GDP [5]) targeted predominantly for social
programs in the LDCs. More needs to be done to clearly inform
the public in these countries that the proportion of their ODA
going to genuine poverty alleviation is only a small fraction of total
ODA.
VPB was proposed as a basic parameter to guide the allocation
of donor funds in an equitable and transparent way [3]. We
propose revising the VPB target upwards from 0.01% to 0.02% of
GDP to reflect a more realistic goal of the costs of including new
vaccines in national immunization programs (Table 1). Monitor-
ing VPB and reporting those national governments (both rich and
poor) that do not provide all recommended vaccines in their
national immunization programs, and yet spend less than 0.02%
GDP for their own vaccine procurement (VPB) could be another
important advocacy tool for non-government organizations,
patient groups, and parents. To accurately monitor VPB, it will
be necessary for all governments to report the amount spent on
their own vaccine procurement for their publicly funded
immunization programs. WHO reports that it will track and
monitor resources invested in immunization on a yearly basis
during the Decade of Vaccines using the newly revised framework
of the OECD/EUROSTAT/WHO System of Health Accounts
[23,24]. Within this framework expenditures on immunization
programs will be monitored – both the time and skills of personnel,
as well as the purchase of vaccines (Figure 1).
We argue that, while it is important to monitor immunization
program costs, a focus on vaccine procurement is justified because
the vaccines are the essential means to provide protection. A
country can have a richly endowed immunization system, but this
is meaningful only when there are vaccines to deliver. Closely
tracking vaccine procurement costs could also provide a monitor-
ing and advocacy tool to drive down vaccine prices. However,
because adequate operational costs are also essential to protect the
investment in vaccines and improve program performance [25], it
would be desirable at a later point to expand the concept of VPA
and VPB and define two new, broader categories:
1. Immunization Program Assistance: official grant financing
from donor governments given for immunization programs in
developing countries.
2. Immunization Program Baseline: share of GDP that govern-
ments spend on their own immunization programs.
The combined concepts of VPA and VPB could provide
transparent metrics to show how much donor countries ‘‘give for’’
vaccine procurement (Figure 5) and how much all countries
‘‘spend on’’ vaccine procurement (Figure 6). The 0.02% of GDP
minimum targets for both VPA and VPB are based on realistic
estimates of what both developed and developing countries can
likely afford. However, the proposed target for VPA should be
seen as preliminary since an important limitation of our study is
the absence of precise OECD purpose codes. Our estimates
included funding specified for immunization programs (OECD
purpose code 12250 for infectious disease control and GAVI
contributions) but may have omitted some funding for vaccine
procurement (OECD purpose code 12220 for basic health care).
Since the current OCED purpose codes are too imprecise to
accurately monitor VPA, it will be necessary for the OECD to
provide new purpose codes that specifically document ODA
disbursed for a) vaccine procurement and b) immunization
programs. Although the complexities of monitoring diverse
ODA expenditures should not be underestimated, particularly in
view of the fact that they will vary between countries and over
VPA and VPB
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time, enhanced and more precise accounting of ODA should be
achievable and will have the added benefit of providing greater
transparency.
In 2009 0.02% of DAC GDP was US$ 7.61 billion (proposed
VPA target) and 0.02% of the GDP of the poorest 117 countries
was US$ 2.88 billion (proposed revised VPB target), which
combines to US$ 10.5 billion and exceeds the US$ 7.6 billion
required annually to achieve the Global Immunization Vision and
Strategy for these 117 countries (Table 1). Documenting the share
of GDP ‘‘given for’’ and ‘‘spent on’’ vaccine procurement could
provide simple and transparent measures to monitor progress in
the mobilization of the financial resources required to achieve the
vision of the Decade of Vaccines and contribute to the Post-2015
Development Agenda.
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